Efficacy and Safety of VX-814 in Alpha 1 PiZZ Genotype

Trial Objective

Efficacy and Safety of VX-814 in Alpha 1 PiZZ GenotypeThe purpose of this study is to learn more about the safety, tolerability and effectiveness of the investigational medication, VX-814, in people with Alpha-1 Antitrypsin Deficiency.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

People who have Alpha-1 Antitrypsin Deficiency may be eligible to participate in this study.

Age: 18-78    Gender: Any Gender


Estimated Time Commitment

42 days

If you are eligible and agree to be in the study, your participation will include a screening period, treatment period and follow-up period. The treatment period will last for 28 days and the follow-up period will last 14 days. In total, you may be asked to visit the study clinic about 8 times.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos
303.270.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals Inc.


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More


*
*
*
*